Beam Therapeutics Files 8-K on Financials and Operations

Ticker: BEAM · Form: 8-K · Filed: Jan 13, 2025

Sentiment: neutral

Topics: financial-reporting, operations, sec-filing

TL;DR

Beam Therapeutics dropped an 8-K detailing financials and operations. Check it out.

AI Summary

Beam Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures related to Regulation FD and other events, along with financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.

Why It Matters

This 8-K filing provides investors with crucial updates on Beam Therapeutics' financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine filing providing financial and operational updates, not indicating immediate significant risk.

Key Players & Entities

FAQ

What specific financial results or operational events are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and 'Other Events', but the specific details are within the attached documents.

When was the earliest event reported in this 8-K filing?

The earliest event reported is January 13, 2025.

What is the principal executive office address for Beam Therapeutics Inc.?

The principal executive offices are located at 238 Main Street, Cambridge, Massachusetts, 02142.

What is the Commission File Number for Beam Therapeutics Inc.?

The Commission File Number for Beam Therapeutics Inc. is 001-39208.

What type of company is Beam Therapeutics Inc. based on its SIC code?

Beam Therapeutics Inc. is classified under SIC code 2836, which pertains to Biological Products (No Diagnostic Substances).

Filing Stats: 1,365 words · 5 min read · ~5 pages · Grade level 15.1 · Accepted 2025-01-13 07:05:57

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2024, Beam Therapeutics Inc. (the "Company") announced in a press release on January 13, 2025 that it estimates that it had cash, cash equivalents and marketable securities of approximately $850.7 million as of December 31, 2024. The information contained in this Item 2.02 regarding the Company's estimated cash balance as of December 31, 2024 is preliminary, unaudited and is subject to completion of the Company's financial statement closing procedures. This estimate also does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024 and its results of operations for the three months and year ended December 31, 2024. Accordingly, undue reliance should not be placed on this preliminary estimate. The information in this Item 2.02 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, the Company updated its corporate presentation that it intends to use in connection with presentations at conferences and meetings, including an investor presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The slides from the Company's corporate presentation are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filling.

01 Other Events

Item 8.01 Other Events. On January 13, 2025, the Company issued a press release announcing progress across its base editing portfolio and outlining key anticipated milestones. The full text of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the website referenced in the press release is not incorporated herein. Cautionary Note Regarding Forward-Looking Statements

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Beam Therapeutics Inc. Corporate Presentation 99.2 Press Release dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEAM THERAPEUTICS INC. Date: January 13, 2025 By: /s/ John Evans John Evans Chief Executive Officer

View on Read The Filing